Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2025 | $5.00 | Speculative Buy | The Benchmark Company |
| 7/28/2025 | $6.00 | Buy | Roth Capital |
The Benchmark Company initiated coverage of CapsoVision with a rating of Speculative Buy and set a new price target of $5.00
Roth Capital initiated coverage of CapsoVision with a rating of Buy and set a new price target of $6.00
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Format: Fireside Chat and 1x1 Investor Meetings Date/Time: Monday, March 23, 2026, at 10:30–10:55 am PT The fireside chat will
SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on Thursday, December 4, 2025 in New York City. If you are interested in arranging a one-on-one meeting with CapsoVision's management team at the conference, please contact your Benchmark representative or reach out to the company
4/A - CapsoVision, Inc (0001378325) (Issuer)
4/A - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
4 - CapsoVision, Inc (0001378325) (Issuer)
8-K - CapsoVision, Inc (0001378325) (Filer)
10-Q - CapsoVision, Inc (0001378325) (Filer)
8-K - CapsoVision, Inc (0001378325) (Filer)
SARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conferen
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ:CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence ("AI") technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the c